Sakar Healthcare Peer Comparison

NSE: SAKAR

₹944.80

₹-1.70 (-0.18%)

As on 30-Oct-2026IST

Market cap

₹2,102 Cr

Revenue (TTM)

₹302 Cr

P/E Ratio

P/B Ratio

6.1

Div. Yield

0 %

Edit

	Sakar Healthcare	Eris Lifesciences	CORONA Remedies	Strides Pharma	Sanofi India
Market cap (₹ Cr)	2,102	16,088	13,125	9,855	7,380
Revenue (₹ Cr)	302	3,330	1,559	5,213	1,822
Net Profit (₹ Cr)	42.87	720.77	206.58	635.98	364.50
Net Margin (%)	14.09	21.60	13.15	11.92	19.81
RoE (%)	12.79	18.93	28.52	17.69	46.28
Price to Earnings	49.04	22.74	63.40	15.98	20.25
Price-To-Book	6.08	3.88	16.30	2.88	7.83

Income Statement (₹ Cr)

	Sakar Healthcare	Eris Lifesciences	CORONA Remedies	Strides Pharma	Sanofi India
Operating Revenue	251.74	3,129.42	1,403.18	4,858.68	1,837.40
Total Income	254.02	3,147.87	1,413.83	5,090.13	1,857.10
Total Expenditure	182.44	2,020.01	1,109.74	4,014.13	1,346.10
EBITDA	69.29	1,109.41	293.44	844.56	491.30
Depreciation	23.56	279.50	37.87	202.40	37.30
EBIT	45.73	829.91	255.57	642.16	454.00
Interest	8.26	192.67	6.97	178.55	1.70
Other Income	2.29	18.45	10.65	231.45	19.70
Exceptional Items	-0.05	-17.24	-19.10	-26.84	-27.30
Profit before Tax	39.76	638.54	240.42	668.69	444.70
Provision for Tax	9.27	-8.97	55.30	94.17	118.00
Profit after Tax	30.48	647.51	185.12	574.52	326.70

	Sakar Healthcare	Eris Lifesciences	CORONA Remedies	Strides Pharma	Sanofi India
Shareholder's Funds	324.45	3,902.67	746.86	3,107.57	749.20
Minority Interest	--	-7.01	--	41.77	--
Non-Current Liabilities	47.02	1,149.84	97.11	598.54	1,159.50
Current Liabilities	109.54	2,201.22	454.53	2,895.49	2,514.20
Total Liabilities	481.01	7,246.72	1,298.50	6,806.56	4,427.30

	Sakar Healthcare	Eris Lifesciences	CORONA Remedies	Strides Pharma	Sanofi India
Non-Current Assets	340.55	5,582.75	856.83	3,030.03	1,599.50
Current Assets	140.46	1,663.97	441.67	3,612.79	2,823.40
Total Assets	481.01	7,246.72	1,298.50	6,806.56	4,427.30
Total Debt*	70.53	2,309.68	142.86	1,668.69	0.00
Net Current Assets	30.92	-537.25	-12.86	717.30	309.20
Contingent Liabilities	--	51.57	1.01	118.51	318.60

	Sakar Healthcare	Eris Lifesciences	CORONA Remedies	Strides Pharma	Sanofi India
Cash From Operating Activities	49.26	537.99	229.48	702.52	438.30
Cash Flow from Investing Activities	-28.35	-369.46	-256.15	-173.04	-11.30
Cash from Financing Activities	-20.96	-313.53	25.28	-453.41	-447.90
Net Cash Inflow / Outflow	-0.05	-145.00	-1.39	76.07	-20.90

	Sakar Healthcare	Eris Lifesciences	CORONA Remedies	Strides Pharma	Sanofi India
ROCE (%)	12.52	14.47	31.74	18.57	55.46
ROE (%)	10.04	19.23	27.36	20.31	44.50
ROA (%)	6.80	9.18	15.99	9.25	7.18
EBIT Margin (%)	28.44	36.04	21.67	22.15	27.81
Net Margin (%)	12.00	20.57	13.09	11.29	17.59
Cash Profit Margin (%)	21.47	28.49	16.17	10.99	17.51

	Sakar Healthcare	Eris Lifesciences	CORONA Remedies	Strides Pharma	Sanofi India
Revenue Growth (%)	41.76	8.15	17.28	6.43	-8.73
EBIT Growth (%)	40.32	8.91	23.66	24.89	0.73
Net Profit Growth (%)	74.18	72.82	23.88	40.33	4.14
EPS Growth (%)	71.83	73.16	23.88	-84.52	4.14
Book Value Growth (%)	14.81	36.71	23.18	21.78	-14.39

	Sakar Healthcare	Eris Lifesciences	CORONA Remedies	Strides Pharma	Sanofi India
Price / Earnings	36.38	29.02	51.41	15.54	28.81
Price / Book Value	3.42	4.62	12.74	2.78	13.89
Dividend Yield (%)	0.00	0.00	0.64	0.53	3.01
EV/EBITDA	16.48	17.93	31.62	9.39	17.88
Market Cap (₹ Cr)	1,109.05	17,980.08	9,517.35	8,643.60	9,410.98

	Sakar Healthcare	Eris Lifesciences	CORONA Remedies	Strides Pharma	Sanofi India
Debt to Equity	0.22	0.59	0.19	0.54	0.00
Short term debt to equity ratio	0.07	0.12	0.17	0.33	--
Current Ratio	1.28	0.76	0.97	1.25	1.12
Quick Ratio	0.64	0.56	0.70	0.68	1.00
Interest Coverage	5.81	4.31	35.49	4.75	262.59

	Sakar Healthcare	Eris Lifesciences	CORONA Remedies	Strides Pharma	Sanofi India
Debtors to sales (%)	19.90	21.74	10.37	26.53	9.62
Asset Turnover	0.56	0.46	1.19	1.14	0.46
Receivable days	58.58	63.88	34.91	64.34	35.69
Inventory Days	82.38	43.27	33.67	75.20	71.21
Payable days	107.49	151.85	203.24	218.23	122.11
Cash Conversion Cycle	33.48	-44.70	-134.66	-78.69	-15.20

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.